Yahoo Finance

• Clinical Trials Revenue Growth: Increased by 9% year-on-year.

• Clinical Trials Sales Contracts: Executed $27 million, down 21% from the prior year.

• Healthcare Revenue Decline: Decreased by 9% due to Eisai agreement renegotiation.

• Profit Before Tax: $7.1 million, more than double the prior year.

• Operating Cash Flow: Improved to $5.8 million from $0.7 million the previous year.

• Net Cash Balance: $29.4 million as of June 30, 2024, up from $27.7 million.

• Gross Profit Margin: Increased by 5 percentage points.

• Operating Expenses: Decreased by 4% year-on-year.

• Future Contracted Revenue: $110.9 million, down 16% year-on-year.

• Clinical Trials Gross Margin Improvement: Increased by 6 points year-on-year.

• New Clinical Trials Sales Contracts: $9.3 million net value executed since July 1, 2024.

• Warning! GuruFocus has detected 1 Warning Sign with FRA:7UM.

Release Date: August 21, 2024

For the complete transcript of the earnings call, please refer to the full earnings call transcript.

Positive Points

• Cogstate Ltd (COGZF) reported a 9% revenue growth in their Clinical Trials segment, showcasing the expansion of their service offerings.

• The company successfully secured four new phase two Alzheimer's programs from different customers, three of which were new to Cogstate, indicating a diversification of their customer base.

• Cogstate Ltd (COGZF) achieved a significant improvement in Clinical Trials gross margins by 6 points, translating a $3.3 million increase in revenue into a $4 million increase in gross profit.

• The renegotiation of the Eisai agreement allowed Cogstate to regain ownership and control over their intellectual property, providing strategic growth opportunities.

• Cogstate Ltd (COGZF) has started the financial year '25 strong, executing an additional $9.3 million of net Clinical Trials sales contracts, indicating a positive outlook for future growth.

Negative Points

• Clinical Trials sales contracts executed were $27 million, down 21% from the prior year, reflecting a decrease in new contract sales.

• The renegotiation of the Eisai agreement resulted in a decline in Healthcare revenue by 9%, impacting the overall revenue mix.

• Future contracted revenue decreased by 16% year-on-year, from $132.6 million to $110.9 million, due to lower Clinical Trials sales and the Eisai agreement renegotiation.

• Cogstate Ltd (COGZF) had to forego $15 million of future payments from Eisai, impacting cash flow expectations for financial years '28 to '31.

• The share buyback program has been suspended, indicating potential concerns about capital allocation or future investment needs.